8 stories found
Patients using GLP-1 receptor agonists like Ozempic are sharing experiences of anhedonia, a neurological side effect that severely diminishes their ability to feel joy or interest in previously rewarding activities.
A recent analysis explores the psychological effects associated with rapid weight loss from GLP-1 receptor agonists, highlighting concerns over mood changes and mental well-being alongside physical results.
GLP-1 receptor agonists and newer GIP/GLP-1 dual agonists have significantly changed obesity treatment, offering substantial and sustainable weight loss, with experts discussing their use during pregnancy.
Despite lacking formal FDA approval for this age group, prescriptions for GLP-1 receptor agonists in children under 12 have skyrocketed, driven by rising childhood obesity rates and associated long-term health risks.
GLP-1 receptor agonists are revolutionizing obesity treatment by achieving significant and sustainable weight loss through their effects on the central nervous system, as discussed by Professor Stavroula Paschou.
Pharmaceutical companies Lilly and Novo Nordisk saw their stock prices increase following a proposal from the FDA to exclude GLP-1 receptor agonists from the compounding list.
Research indicates that patients using GLP-1 receptor agonists for diabetes and obesity face a higher risk of hair loss compared to users of other medications.
New research suggests that GLP-1 receptor agonists, drugs typically used for type 2 diabetes and obesity, may possess anti-inflammatory properties beneficial for patients with dermatological diseases. This finding comes from a summary of current knowledge on their application in dermatology.